Acalabrutinib is an anti-cancer medicine (tyrosine kinase inhibitor) showing promise in early studies. Its potential mechanism of action (MoA) is poorly understood. If understood better, more anti-cancer drugs can be rationalized against COVID-19. MoA elements include genes, and pathways that may explain the MoA of the drug in particularly ameliorating cytokine storm-related features in COVID-19.
Tags: ACALABRUTINIB, CCL3, CCL4, CD19, CD20, CELL DIFFERENTIATION, CHEMOKINE PRODUCTION, COMPLEMENT ACTIVATION, COVID-19, CXCL10, CYTOKINE STORM, EGFR, ENDOCYTOSIS, IFNG, IL10, IL6, IMMUNE RESPONSE, LACTATE DEHYDROGENASE, LYMPHOCYTE ACTIVATION, METHYLATION, MYD88, NEGATIVE REGULATION OF KINASE ACTIVITY, NFKB1, NK, PD-1, PHAGOCYTOSIS, PI3K, PLATELET ACTIVATION, SARS-COV-2, SECRETION, TNF